|Bid||118.19 x 100|
|Ask||120.95 x 100|
|Day's Range||118.19 - 120.74|
|52 Week Range||81.12 - 121.75|
|PE Ratio (TTM)||39.34|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On June 16, 2017, a German court awarded "co-entitlement" rights to Edwards Lifesciences' (EW) subsidiary CardiAQ valve to the Tiara European patent application of Neovasc.
On June 5, 2017, Edwards Lifesciences (EW) received FDA approval for its Sapien 3 transcatheter heart valve for aortic and mitral valve-in-valve procedures.
Edwards Lifesciences (EW) is one of the leading players in the artificial valve market. After falling toward the end of 2016, EW stock has recovered recently and returned ~26.5% year-to-date.